Tumor markers in pleural effusion diagnosis

Area of Science:

• Oncology
• Pulmonology
• Clinical Chemistry

Background:

• Distinguishing malignant from benign pleural effusions is crucial for patient management.
• Various biomarkers have been investigated for their diagnostic utility in pleural effusions.

Purpose of the Study:

• To evaluate the effectiveness of carcinoembryonic antigen (CEA), ferritin, beta2-microglobulin (BMG), acid-soluble glycoprotein (ASP), tissue polypeptide antigen (TPA), adenosine deaminase (ADA), and immunosuppressive acidic protein (IAP) in differentiating malignant and benign pleural effusions.
• To assess the role of these markers in lung cancer and other malignancies.

Main Methods:

• Pleural fluid samples were analyzed from patients with lung cancer, other malignancies, tuberculous pleurisy, and benign diseases.
• Levels of CEA, ferritin, BMG, ASP, TPA, ADA, and IAP were measured.
• Statistical analysis was performed to compare marker levels between different groups.

Main Results:

• Significantly higher CEA levels were observed in malignant effusions compared to benign ones.
• Elevated pleural fluid CEA was found in 68% of lung cancer patients and 44% of other malignancy patients.
• In lung cancer cases with negative cytology, nine out of 13 showed elevated CEA.
• Mean ADA activity was significantly higher in tuberculous effusions than in other causes.
• Pleural fluid BMG levels showed overlap between malignant and benign diseases.
• No significant differences in ferritin, ASP, TPA, and IAP levels were found between malignant and benign conditions.

Conclusions:

• Pleural fluid CEA is a valuable marker for discriminating malignant from benign effusions, especially in cases where cytology is negative.
• ADA activity is a useful indicator for tuberculous pleurisy.
• Further research may be needed to clarify the role of BMG, ASP, TPA, and IAP.